Familial Colorectal Cancers - Familial Adenomatous Polyposis (FAP)
Colorectal cancer accounts for 8.4% of all cancer deaths in the United States. There will be an estimated 135,400 new cases and 50, 260 deaths in the United States in 2017. Approximately 10 to 15% of these cancers may be caused by genetic abnormalities that run in families. There are two major types of known hereditary disorders, familial adenomatous polyposis (also known as FAP) and hereditary nonpolyposis colorectal cancer (also known as HNPCC). In this article, we will address FAP.
FAP is very rare. It accounts for less than one percent of new colorectal cancer cases each year. Estimates of the incidence of FAP vary from 1 case in 6,850 persons to 1 case in 31,250 persons. About 15% of people with FAP develop polyps by the age of 10, and 90% develop them by the age of 30. Affected patients can develop hundreds to thousands of adenomatous polyps. People with FAP have a 100% chance of developing colorectal cancer by age 40 if they do not have their colon removed.
Adenomatous polyps are considered to be "pre-cancerous" lesions, some of which will eventually progress to cancer. Therefore, the more polyps an individual has, the greater his or her chance of developing cancer. The average age of colorectal cancer diagnosis in FAP is 39 years, as compared to 72 years in the general population.
Colon with multiple adenomas, Photo courtesy of Zane Cohen Centre for Digestive Disorders, Mt. Sinai Hospital, Toronto, Canada.
Several other cancers have been associated with FAP, including periampullary and thyroid cancer. Periampullary (cancer that is found in the area where the bile duct and pancreas empty into the small bowel) is the second most common cancer in FAP, and accounts for 1 in 5 deaths of these patients. In addition, several other non-cancerous manifestations have been seen in FAP. Young FAP patients may develop cysts in the skin on the face, scalp, arms, and legs, often years before they develop colon polyps. Congenital hypertrophy of the retinal pigment epithelium (also called CHRPE) is an abnormality found in the retina of the eye that looks like a freckle and causes no symptoms for the patient. While CHRPE can be seen in one eye of individuals without FAP, but it is often present in both eyes in an FAP patient. About 70% of FAP patients have dental abnormalities, including extra or missing teeth, fused roots, or non-cancerous tumors of the jaw bone (osteomas). Although these manifestations are not harmful to the patient, they may be the first sign of FAP and prompt a patient to undergo testing for FAP.
Ten percent of FAP patients will develop desmoid tumors, which are non-cancerous, slow-growing tumors that occur in the abdominal area. Despite the fact that these tumors are not cancerous, they can cause significant damage by surrounding, compressing, and eroding nearby structures, and may need to be removed surgically. In the past, the term "Gardner's Syndrome" was used to describe a subset of FAP patients that have CHRPE, dental abnormalities or desmoid tumors, and was thought to be genetically different. It is now known that these features are seen in many FAP patients and these cases are not genetically different.
Congenital hypertrophy of the retinal pigment epithelium, Photo courtesy of Zane Cohen Centre for Digestive Disorders, Mt. Sinai Hospital, Toronto, Canada.
Genetics and Screening
In 1991, the gene responsible for FAP was discovered and was named the Adenomatous Polyposis Coli, or APC gene. Scientists have discovered over 300 different mutations in the APC gene which can cause FAP. The location of the mutation on the gene often correlates with the number of polyps, age of onset, and other manifestations. FAP is an autosomal dominant inherited disorder, meaning that a child of an affected parent has a 50% chance of inheriting the mutation. Approximately 30% of FAP cases are "de novo mutations", meaning they have no prior family history of the mutation.
The diagnosis of FAP is made by discovering >100 adenomatous polyps or through genetic testing in a known FAP family. Once a person is diagnosed, an analysis of the family should be done to determine the likelihood that other relatives have the condition. Genetic testing can identify the specific abnormality in the affected individual, and then look for this defect in other family members. It is recommended that children of FAP patients undergo genetic testing or endoscopic screening by age 10. If genetic tests are positive in these children, endoscopic screening should continue every 1 to 2 years. If genetic testing is negative, these people can be spared the intensive screening.
Genetic testing is something that should not be taken lightly. One must consider the affect of the test results on themselves and other family members. Concerns may include the implication of a positive or negative test, passing the gene on to children, and discrimination in employment and insurance matters. A genetic counselor should meet with anyone wishing to undergo testing, both before testing and after the results are known. These professionals are trained to help patients understand the risks and benefits of testing and what to do with the results.
There is no medication to prevent the development of colon polyps in FAP. However, aspirin and some non-steroidal anti-inflammatory drugs (NSAIDS such as sulindac and indomethacin) have been shown to shrink or reduce polyp development in these patients. A recent clinical trial examined the benefits of a targeted therapy medication, erlotinib in combination with sulindac. Clinical trials are currently examining ways to prevent polyp growth in these patients.
Until better medical therapies are developed, individuals with FAP require surgical removal of their colon to prevent the development of colon cancer. This surgery is often performed between the ages of 17 and 20 in asymptomatic members of FAP families. There are several surgical options for these patients, but the goal is to remove all colorectal tissue at risk for developing polyps and maintain normal bowel evacuation through the anus.
FAP is one of the most well understood inherited cancer syndromes. This knowledge has led to the availability of genetic testing for at risk individuals, improved screening and surgical management, and clinical trials for the prevention of polyp formation. Continued research into FAP will lead to better treatments for these families, and may have implications for all colon cancer patients.
Resources for More Information
Hereditary Colon Cancer Foundation http://www.hcctakesguts.org/
Learn more about surgical options for FAP, at the Zane Cohen Centre for Digestive Diseases/Mt Sinai Hospital, Toronto Canada.
Learn more about the ileo-anal anastomosis procedure and support.
Find a genetic counselor in your area.
Learn more about cancer family registries.
SEER Statistics: Colon and Rectum Cancer. https://seer.cancer.gov/statfacts/html/colorect.html
A Guide for Families: Familial Adenomatous Polyposis. http://www.zanecohencentre.com/gi-cancers/diseases/fap
ASCO, Familial Adenomatous Polyposis. http://www.cancer.net/cancer-types/familial-adenomatous-polyposis
Arber, N., Eagle, C. J., Spicak, J., Rácz, I., Dite, P., Hajer, J., ... & Rosenstein, R. B. (2006). Celecoxib for the prevention of colorectal adenomatous polyps. New England Journal of Medicine, 355(9), 885-895.
Asano, T. K., & McLeod, R. S. (2004). Nonsteroidal anti-inflammatory drugs and aspirin for the prevention of colorectal adenomas and cancer: a systematic review. Diseases of the Colon & Rectum, 47(5), 665-673.
Cruz–Correa, M., Hylind, L. M., Romans, K. E., Booker, S. V., & Giardiello, F. M. (2002). Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology, 122(3), 641-645.
Eeson, G., Cleary, S., Carol-anne, E. M., & Ridgway, P. F. (2016). Ampullary Cancer. In Surgical Oncology Manual (pp. 13-19). Springer International Publishing.
Paraf, F., Olschwang, S., Nihoul-Fékété, C., Kazandjian, V., Brousse, N., & Schmitz, J. (1996). Familial adenomatous polyposis and thyroid cancer. Gastroenterologie Clinique et Biologique, 21(1), 74-77.
Samadder, N. J., Neklason, D. W., Boucher, K. M., Byrne, K. R., Kanth, P., Samowitz, W., ... & Jasperson, K. (2016). Effect of sulindac and erlotinib vs placebo on duodenal neoplasia in familial adenomatous polyposis: a randomized clinical trial. Journal of the American Medical Association, 315(12), 1266-1275.
Vasen, H. F., Moeslein, G., Alonso, A., Aretz, S., Bernstein, I., Bertario, L., ... & Colas, C. (2008). Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut, 57(5), 704-713.
Wehbi, M., et.al. (2016) Familial Adenomatous Polyposis. http://emedicine.medscape.com/article/175377-overview#a6, retrieved 7 June 2017